Drug intelligence / Profile preview

VR2076

Development stage: Preclinical
Lead developer: Phillips-Medisize
Modality: Small Molecules
Administration: Inhalation

Overview

VR2076 (formerly known as SKP-2076) is a novel inhaled triple combination therapy consisting of an inhaled corticosteroid (ICS), a long-acting beta2-adrenergic agonist (LABA), and a long-acting muscarinic antagonist (LAMA). It is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug is formulated as an aerosol inhaler to provide comprehensive management of respiratory conditions by targeting inflammation, bronchoconstriction, and airway hyperresponsiveness. Initial development was led by Vectura in partnership with Mundipharma, which has assumed global responsibility for further development and commercialization[5].

Other names: SKP-2076SKP2076SKP 2076VR 2076VR2076VR-2076

Targets

ADRB2 (β2)GR (Glucocorticoid receptor)CHRM3 (M3)

Beyond the preview

Go deeper on VR2076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VR2076.

Explore the full profile